ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Monocytes/macrophages"

  • Abstract Number: 0944 • ACR Convergence 2024

    Targeting Defective Macrophages to Restore Resolution of Inflammation in Rheumatoid Arthritis -Perspectives for an Autologous Secretome Therapy

    Melanie Couturier1, Francis Bonnefoy2, emilie Gaiffe3, Charline Vauchy4, Suzanne Behlke2, ERIC TOUSSIROT5 and Sylvain Perruche2, 11MED’INN’Pharma, F-25000 Besançon, France, Besançon, France, 2MED’INN’Pharma, F-25000 Besançon, France, Besançon, France, 3INSERM CIC -1431 CHU Besançon, France, Besançon, France, 4INSERM CIC-1431, CHU de Besançon, Besancon, France, Besançon, France, 5university hospital of BESANCON, besancon, France

    Background/Purpose: Impaired macrophage efferocytosis, a key hallmark of failed inflammation resolution, is reported in many immune-mediated inflammatory diseases, including in Rheumatoid Arthritis (RA). Hence the…
  • Abstract Number: 0946 • ACR Convergence 2024

    Tissue Resident Monocyte-lineage Cells (TR-MC) Exist as Two Different Subpopulations

    Yidan Wang1, Jessica Maciuch2, Tyler Therron3, Carla Cuda2, Deborah Winter4 and Harris Perlman2, 1Northwestern University, Hanover Park, IL, 2Northwestern University, Chicago, IL, 3Northwestern University, Chicago, 4Northwestern University, Skokie, IL

    Background/Purpose: Monocytes are critical for the pathogenesis of rheumatoid arthritis (RA). However, depletion of peripheral monocytes (PM) is not sufficient to rescue disease in RA…
  • Abstract Number: 0962 • ACR Convergence 2024

    Characterizing the Contribution of Myeloid Cells to Limited and Diffuse Cutaneous Systemic Sclerosis

    Parker Jones1, Salina Dominguez2, Miranda Gurra3, Gaurav Gadhvi4, Tyler Therron2, Kathleen Aren5, Carla Cuda3, Monique Hinchcliff6, Harris Perlman3, Hadijat Makinde3 and Deborah Winter7, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Northwestern University, Chicago, 3Northwestern University, Chicago, IL, 4University of Michigan, Ann Arbor, MI, 5Northwestern University Division of Rheumatology, Chicago, IL, 6Yale School of Medicine, Westport, CT, 7Northwestern University, Skokie, IL

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by multiorgan fibrosis. The two main subtypes are diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc…
  • Abstract Number: 0970 • ACR Convergence 2024

    Deubiquitylase (DUB) BRCC36 Isopeptidase Complex (BRISC) Inhibitors Prevent IFNAR1 Deubiquitination to Restore Natural Type I IFN Response in Autoimmunity

    Rebecca Ross1, Poli Adi Narayanna Reddy2, Joseph Salvino2, Elton Zeqiraj3 and Francesco Del Galdo3, 1Medicine and Health, University of Leeds, Leeds, United Kingdom, 2The Wistar Institute, Philadelphia, PA, 3University of Leeds, Leeds, United Kingdom

    Background/Purpose: Increased Type I IFN activation plays a key role in Scleroderma (SSc), Systemic Lupus Erythematosus and Inflammatory Myositis. Deubiquitylase (DUB) BRCC36 isopeptidase complex (BRISC)…
  • Abstract Number: 1139 • ACR Convergence 2024

    Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes

    Shinji Izuka1, Toshihiko Komai2, Hayato Yuuki2, Ikuko Ueda3, Manabu Fujimoto4, Hiroyuki Fukui5, Masaru Takeshita6, Natsuka Umezawa7, Shinsuke Yasuda7, Mitsutaka Yasuda8, Yuichiro Fujieda9, Tatsuya Atsumi9, Takeshi Iwasaki10, Akio Morinobu10, Yuya Kondo11, Isao Matsumoto11, Toshio Kawamoto12, Masakazu Matsushita12, Naoto Tamura13, Taro Iwamoto14, Hiroshi Nakajima14, Ken Yoshida15, Takeo Isozaki16, Nobuyuki Yajima16, Keiichi Sakurai17, Kimito Kawahata17, Yasuyuki Kamata18, Kojiro Sato18, Yoshiya Tanaka19, Akari Suzuki20, Kazuhiko Yamamoto21, Tomohisa Okamura22 and Keishi Fujio2, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Tokyo, Japan, 2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, 3Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Japan, 4Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Osaka, Japan, 5Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Tokyo, Japan, 6Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 7Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Tokyo, Japan, 8Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Sapporo, Japan, 9Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 10Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan, 11Department of Rheumatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Tsukuba, Japan, 12Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., Tokyo, Japan, 13Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 14Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan., Chiba, Japan, 15Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Tokyo, Japan, 16Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, 17Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan., Kawasaki, Japan, 18Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan., Tochigi, Japan, 19Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 20Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kanagawa, Japan, 21Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kawasaki, Japan, 22Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are heterogeneous diseases, making it crucial to identify distinct pathological processes to improve a treatment strategy. Transcriptomic analyses have revealed…
  • Abstract Number: 1421 • ACR Convergence 2024

    Differential Impact of B-cell Targeted Monotherapy and Combination Regimen on the Peripheral Blood Transcriptome of Adults with Active Sjögren Disease

    Coziana Ciurtin1, Lucia Martin-Gutierrez1, John Casement2, Kyle Thompson3, Fai Ng4, Andre van Maurik5 and Elizabeth Jury1, 1University College London, London, United Kingdom, 2Newcastle University, Newcastle, United Kingdom, 3Newcastle University, Newcastle, England, United Kingdom, 4Newcastle University, Newcastle upon Tyne, England, United Kingdom, 5Precision Medicine, GlaxoSmithKline, Stevenage, United Kingdom

    Background/Purpose: Sjögren disease (SD) is characterised by B-cell hyperactivity associated with increased levels of B-lymphocyte stimulator (BlyS), but there are no effective biologic treatments for…
  • Abstract Number: 1656 • ACR Convergence 2024

    Loss of Nr4a1 Expression Protects Cartilage During Post-traumatic Osteoarthritis

    Katherine Escalera-Rivera, Jennifer Jonason and Jennifer Anolik, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Osteoarthritis (OA) is a complex disease involving pathological processes in joint tissues such as the cartilage and synovium. Cartilage is degraded by matrix metalloproteinases…
  • Abstract Number: 1712 • ACR Convergence 2024

    Transcriptome Analysis Characterizes the Role of Monocytes in Ankylosing Spondylitis with TNF-blocker Treatment

    Yulong Tang1, Jiangnan Xie2, Dachun Zhuo1, Qi ZHU3, Jiucun Wang1 and Jing Liu2, 1Fudan University, Shanghai, China (People's Republic), 2Fudan University, Shanghai, Shanghai, China (People's Republic), 3Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China (People's Republic)

    Background/Purpose: Ankylosing spondylitis (AS) is an autoimmune and auto-inflammatory disease characterized by chronic inflammation of the spine, sacroiliac joint, and occasionally peripheral joints. TNF-α inhibitor…
  • Abstract Number: 1765 • ACR Convergence 2024

    CD8+ T Cells and Monocytes from Children with Macrophage Activation Syndrome Demonstrate Specific Transcriptional Changes Consistent with T Cell Activation and Expansion of Monocytes Shaped by Interferon and TLR Signaling

    Susan Canny1, Hannah DeBerg2, Griffin Gessay2, Ailing Lu3, Mary Eckert4, Andrea La Bella5, Hayley Waterman2, Danish Nadeem2, Susan Shenoi6, Joyce Hui-Yuen7, Daniel Campbell2, Betsy Barnes8 and Jessica Hamerman2, 1University of Washington, Seattle, WA, 2Benaroya Research Institute, Seattle, WA, 3Northwell Health, Manhasset, NY, 4Seattle Children's Hospital, Seattle, WA, 5Cohen Children's Medical Center, Queens, NY, 6Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, 7North Shore LIJ Health System, Great Neck, NY, 8Feinstein Institutes for Medical Science, Manhasset, NY

    Background/Purpose: Macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (sHLH), is a potentially fatal complication of rheumatic diseases. MAS is characterized by a…
  • Abstract Number: 1789 • ACR Convergence 2024

    Multi-omic Profiling Identifies Pathogenic Pro-inflammatory Human Monocytes/Macrophages in Systemic Lupus Erythematosus

    Lais Osmani1, Min Shin2, Sang Jin Lee3, Helen Cai4, Won Jae Seong2, Hyoungsu Kim2, Jongjin Yoo2, Angela Mirabella2, William Bracamonte2, Mario Felix5, Jong Gyun Ahn2, Hong-Jai Park2, Juan Young6, Junghee Shin2, Serhan Unlu7, Noelle Yoo2, Edward Doherty2, Jiaye Chen2, Chenxi Li2, Gabriela Sanchez-Zuno2, Caroline Valdez4, Thuy Tran8, Mei Dong2, Sang Kim2, Christine Ko9, Sungyong You10, Jose Gomez11, Richard Bucala12 and Insoo Kang2, 1Yale, New Haven, CT, 2Yale University School of Medicine, Internal Medicine (Rheumatology, Allergy & Immunology), New Haven, CT, 3Division of Rheumatology, Kyungpook National University Hospital, Dae gu, Republic of Korea, 4Yale University School of Medicine, New Haven, CT, 5Yale, Hamden, CT, 6Yale University School of Medicine, Psychiatry, New Haven, CT, 7Cleveland Clinic, Internal Medicine, Cleveland, OH, 8Yale University School of Medicine, Internal Medicine (Medical Oncology), New Haven, CT, 9Yale University School of Medicine, Dermatology and Pathology, New Haven, CT, 10Cedars-Sinai Medical Center, Surgery and Computational Biomedicine, Los Angeles, CA, 11Yale University School of Medicine, Internal Medicine (Pulmonary, Critical Care & Sleep), New Haven, CT, 12Yale University School of Medicine, Internal Medicine (Rheumatology, Allergy & Immunology) and Pathology, New Haven, CT

    Background/Purpose: Systemic lupus erythematosus (SLE or lupus) is a clinically heterogeneous autoimmune disease, in which emerging evidence implicates the innate immune system, particularly monocytes and…
  • Abstract Number: 0004 • ACR Convergence 2024

    Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells

    Daniel Capon, Larisa Troitskaya, Marina Fomin, Brendon Frank, Ursula Edman, Benjamin Capon, Brian Law, Steven Chapin, Gavin Lewis, Malcolm Gefter, Juha Punnonen and Nelson Chan, Hinge Bio, Inc., Burlingame, CA

    Background/Purpose: The dramatic demonstration of CD19 CAR-T efficacy in systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis by Georg Schett and colleagues (F.…
  • Abstract Number: 1782.5 • ACR Convergence 2024

    Monocytes from HLA B27 Positive Enthesitis Related Arthritis Patients Are More Activated Than HLA B27 Negative Patients

    Shivika Guleria1, Anu Balakrishnan1, Able Lawrence1 and Amita Aggarwal2, 1SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Enthesitis related arthritis (ERA) is a chronic immune-inflammatory disease with unknown etiology. HLA-B27 is the strongest risk factor predisposing to ERA similar to Spondylarthritis…
  • Abstract Number: 0014 • ACR Convergence 2024

    Phenotypic Validation of Humanized IgA1 and CD89 Transgenic Mice as a Model for IgA Nephropathy-Like Autoimmune Disease

    Kaiyuan Zi and Juan Liang, GemPharmatech, San Diego

    Background/Purpose: The etiology of IgA nephropathy (IgAN) remains only partly understood, but the presence of IgA antibodies together with the myeloid IgA-receptor FcαRI/CD89 complexes in…
  • Abstract Number: 1808 • ACR Convergence 2024

    Not Only Type-I Interferon Regulated Genes Are Differentially Expressed in Circulating Monocytes from Active Lupus Nephritis Patients

    Paula Losada Vanegas1, Juan Antonio Villatoro-García2, Daniel Rodriguez3, Juan Camilo Diaz3, Ricardo Pineda4, Pedro Carmona-Saez5, Mauricio Rojas6 and Gloria Vasquez7, 1Universidad de Antioquia, Medellin, Antioquia, Colombia, 2GENYO (Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Andalucia, Spain, 3ARTMEDICA, Medellín, Antioquia, Colombia, 4ARTMEDICA, Medellin, Antioquia, Colombia, 5GENYO (Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Asturias, Spain, 6Grupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria. Facultad de Medicina. Universidad de Antioquia, Medellin, Antioquia, Colombia, 7Grupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria. Facultad de Medicina.Universidad de Antioquia, Medellin, Colombia

    Background/Purpose: Monocytes play an important role in organ damage, such as in Lupus Nephritis (LN). Although monocytes are typically considered inflammatory cells, evidence shows they…
  • Abstract Number: 0058 • ACR Convergence 2024

    Bradykinin Receptor B1 Blockade Suppresses Soluble CD13-Induced Differentiation of Osteoclasts from Monocytes

    Sei Muraoka1, Qi Wu2, Mikel Gurrea-Rubio3, Camila Amarista2, William Brodie2, Megan Mattichak2, Yuzo Ikari4, Caroline Foster2, Phillip Campbell2, David Fox5 and Pei-Suen Tsou2, 1University of Michigan, Toyko, Japan, 2University of Michigan, Ann Arbor, MI, 3University of Michigan - Ann Arbor, Ann Arbor, MI, 4Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 5University of Michigan, Dexter, MI

    Background/Purpose: CD13 is an ectopeptidase expressed on myeloid cells, endothelial cells, and rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS). Soluble (s) CD13 is generated by matrix…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology